Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents

References

• Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue. and long-term outcome. Oncology 2005;69(Suppl 2):2-7
   PubMed Web of Science ®Google Scholar
• Nieboer P, Buijs C, Rodenhuis S, et al. Fatigue and relating factors in high-risk breast cancer patients treated with adjuvant standard or high-dose chemotherapy: a longitudinal study. J Clin Oncol 2005;23(33):8296-304
   PubMed Web of Science ®Google Scholar
• Goodnough LT, Shander A. Current status of pharmacologic therapies in patient blood management. Anesth Analg 2013;116(1):15-34
   PubMed Web of Science ®Google Scholar
• Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006;3:CD003407
   PubMedGoogle Scholar
• Ross SD, Allen IE, Henry DH, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006;28(6):801-31
   PubMed Web of Science ®Google Scholar
• Goodnough LT, Shander A. Patient blood management. Anesthesiology 2012;116(6):1367-76
   PubMed Web of Science ®Google Scholar
• Goodnough LT, Levy JH, Murphy MF. Concepts of blood transfusion in adults. Lancet 2013;381(9880):1845-54
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23(25):5960-72
   PubMed Web of Science ®Google Scholar
• Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362(9392):1255-60
   PubMed Web of Science ®Google Scholar
• Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26(7):1040-50
   PubMed Web of Science ®Google Scholar
• Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25(9):1027-32
   PubMed Web of Science ®Google Scholar
• Juneja V, Keegan P, Gootenberg JE, et al. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer. Clin Cancer Res 2008;14(11):3242-7
   PubMed Web of Science ®Google Scholar
• Public Health Advisory: Erythropoiesis-stimulating agents (ESAs). United States Food & Drug Administration. Available from: www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm124262.htm [Last accessed 27 August 2013]
   Google Scholar
• FDA drug safety communication: Erythropoiesis-stimulating agents (ESAs): Procrit, Epogen and Aranesp. United States Food & Drug Administration. Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm [Last accessed 1 November 2013]
   Google Scholar
• Hagerty K. Continued regulatory actions affecting the use of erythropoiesis-stimulating agents. J Oncol Pract 2008;4(6):267-70
   PubMedGoogle Scholar
• Goodnough LT, Shander AS. Erythropoiesis stimulating agents, blood transfusion, and the practice of medicine. Am J Hematol 2010;85(11):835-7
   PubMed Web of Science ®Google Scholar
• Goodnough LT. Blood management: transfusion medicine comes of age. Lancet 2013;381(9880):1791-2
   PubMed Web of Science ®Google Scholar
• Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. First of two parts – blood transfusion. N Engl J Med 1999;340(6):438-47
   PubMed Web of Science ®Google Scholar
• Williamson LM. Transfusion associated graft versus host disease and its prevention. Heart 1998;80(3):211-12
   PubMed Web of Science ®Google Scholar
• Sheppard CA, Logdberg LE, Zimring JC, Hillyer CD. Transfusion-related acute lung injury. Hematol Oncol Clin North Am 2007;21(1):163-76
   PubMed Web of Science ®Google Scholar
• Arneson TJ, Li S, Gilbertson DT, et al. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients. Pharmacoepidemiol Drug Saf 2012;21(8):857-64
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S, Zhou XA, Sizer K, et al. Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions. Oncologist 2010;15(12):1359-69
   PubMed Web of Science ®Google Scholar
• Feinberg B, Gilmore J, Gondesen T, et al. Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: results from a community oncology practice. Community Oncol 2009;6(6):257-61
   Google Scholar
• Henry DH, Langer CJ, McKenzie RS, et al. Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review. Support Care Cancer 2012;20(9):2089-96
   PubMed Web of Science ®Google Scholar
• Hess G, Nordyke RJ, Hill J, Hulnick S. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions. Am J Hematol 2010;85(11):838-43
   PubMed Web of Science ®Google Scholar
• Lal LS, Raju A, Miller LA, et al. Impact of changes in reimbursement policies and institutional practice algorithm for utilization of erythropoietic-stimulating agents on treatment patterns and costs in anemic lymphoma patients. Support Care Cancer 2010;19(2):251-9
   PubMed Web of Science ®Google Scholar
• Yu JM, Shord SS, Cuellar S. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia. J Oncol Pharm Pract 2011;17(4):360-5
   PubMedGoogle Scholar
• Hill JW, Cong Z, Hess G, et al. Hemoglobin decline in chemotherapy patients prior to and after policy changes affecting use of erythropoiesis-stimulating agents: 2006-2009. J Int Med Res 2012;40(4):1532-45
   PubMed Web of Science ®Google Scholar
• Feinberg BA, Bruno AS, Haislip S, et al. Hemoglobin trends and anemia treatment resulting from concomitant chemotherapy in community oncology clinics. J Oncol Pract 2012;8(1):18-23
   PubMedGoogle Scholar
• Ferrajoli A, Buzdar AU, Dejesus Y, et al. Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for anemia. Cancer 2011;117(14):3268-75
   PubMed Web of Science ®Google Scholar
• Boone JD, Fauci JM, Walters CL, et al. The effect of the APPRISE mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapy. Int J Gynecol Cancer 2013;23(2):367-71
   PubMed Web of Science ®Google Scholar
• Henk HJ, Cong Z, DaCosta Byfield S, Nordyke RJ. Trends in transfusion incidence among cancer patients receiving chemotherapy (2005-2008). Presented at American Society of Clinical Oncology 2010 Annual Meeting; Chicago, IL, USA; 2010. p. e19506
   Google Scholar
• Mueller CS, Chastek B, Newcomer LN, et al. Impact of erythropoiesis-stimulating agent (ESA) reimbursement policy change on transfusion frequency for patients with chemotherapy-induced anemia (CIA). Presented at American Society of Clinical Oncology 2010 Annual Meeting; Chicago, IL, USA; 2010. p. e16507
   Google Scholar
• Burton T, Larholt K, Apgar E, et al. Pre- vs. post-national coverage determination (NCD) blood utilization and hemoglobin values among Medicare patients treated with erythropoietic-stimulating agents (ESAS) for chemotherapy-induced anemia (CIA). Presented at 50th Annual Meeting of the American Society of Hematology; San Francisco, CA, USA; 2008. p. 1301
   Google Scholar
• Burton T, Boulanger L, Larholt K, et al. Blood and resource utilization in cancer patients with chemotherapy-induced anemia (CIA) in the pre- and post-national coverage determination (NCD) timeframes: results from an electronic medical record study. Presented at 51st Annual Meeting of the American Society of Hematology; New Orleans, LA, USA; 2009. p. 2472
   Google Scholar
• Batty N, Ghonimi E, Feng L, et al. Blood transfusion and erythropoiesis stimulating agents (ESAs) use in patients with diffuse large B-cell lymphoma (DLBCL). Presented at 52nd Annual Meeting of the American Society of Hematology; Orlando, FL, USA; 2010. p. 3357
   Google Scholar
• Apgar E, Burton TM, Larholt K, et al. Hematologic and hospitalization outcomes in patients with chemotherapy-induced anemia (CIA) treated with erythropoiesis-stimulating agents (ESAs) in the pre- vs post-national coverage determination (NCD) time periods. Presented at 51st Annual Meeting of the American Society of Hematology; New Orleans, LA, USA; 2009. p. 2482
   Google Scholar
• Dickinson KM, Sakr BJ. ESA use in women with cancer: Consequences of the 2008 FDA clinical alert. Presented at American Society of Clinical Oncology 2012 Annual Meeting; Chicago, IL, USA; 2012. p. 5040
   Google Scholar
• Naeim A, Glaspy J. Changes in RBC supportive medications and transfusions in cancer patients undergoing chemotherapy before and after FDA and Medicare actions in 2007. Presented at American Society of Clinical Oncology 2008 Annual Meeting; Chicago, IL, USA; 2008. p. 20595
   Google Scholar
• Dibona J, Lichtig L, Green L. Retrospective cohort study of transfusion rates in cancer patients before and after implementation of the Medicare national coverage determination (NCD) restricting coverage for erythropoiesis-stimulating agents (ESAs). Presented at American Society of Health-System Pharmacists 2009 Summer Meeting; Rosemont, IL, USA; 2009
   Google Scholar
• Tarlov E, Stroupe KT, Lee TA, et al. Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002-2008. Support Care Cancer 2012;20(8):1649-57
   PubMed Web of Science ®Google Scholar
• Larholt K, Burton TM, Hoaglin DC, et al. Clinical and patient-reported outcomes based on achieved hemoglobin levels in chemotherapy-treated cancer patients receiving erythropoiesis-stimulating agents. Community Oncol 2009;6(9):403-8
   Google Scholar
• Deger M, Eisterer W, Kutikova L, Salek S. Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe. Support Care Cancer 2013;21(2):485-93
   PubMed Web of Science ®Google Scholar
• Canon JL, Vansteenkiste J, Hedenus M, et al. Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus >/= 10 g/dL: an exploratory analysis of a phase 3 trial. Med Oncol 2012;29(3):2291-9
   PubMed Web of Science ®Google Scholar
• Spahn DR, Goodnough LT. Alternatives to blood transfusion. Lancet 2013;381(9880):1855-65
   PubMed Web of Science ®Google Scholar
• Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28(33):4996-5010
   PubMed Web of Science ®Google Scholar
• Schrijvers D, De Samblanx H, Roila F, ESMO Guidelines Working Group. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 2010;21(Suppl 5):v244-7
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network®. NCCN clinical practice guidelines in oncology: cancer- and chemotherapy-induced anemia. Version 3. 2014. Available from: www.nccn.org/professionals/physician_gls/pdf/anemia.pdf [Last accessed 6 June 2014]
   Google Scholar
• Berger ML, Mamdani M, Atkins D, Johnson ML. Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report – Part I. Value Health 2009;12(8):1044-52
   PubMed Web of Science ®Google Scholar
• Cox E, Martin BC, Van Staa T, et al. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analysis Task Force Report – Part II. Value Health 2009;12(8):1053-61
   PubMed Web of Science ®Google Scholar
• Dreyer NA, Schneeweiss S, McNeil BJ, et al. GRACE principles: recognizing high-quality observational studies of comparative effectiveness. Am J Manag Care 2010;16(6):467-71
   PubMed Web of Science ®Google Scholar
• Johnson ML, Crown W, Martin BC, et al. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report – Part III. Value Health 2009;12(8):1062-73
   PubMed Web of Science ®Google Scholar
• Motheral B, Brooks J, Clark MA, et al. A checklist for retrospective database studies – report of the ISPOR Task Force on Retrospective Databases. Value Health 2003;6(2):90-7
   PubMed Web of Science ®Google Scholar
• Sax MJ. Essential steps and practical applications for database studies. J Manag Care Pharm 2005;11(1 Suppl A):S5-8
   PubMedGoogle Scholar
• Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27(4):299-309
   PubMed Web of Science ®Google Scholar
• Zhang F, Wagner AK, Soumerai SB, Ross-Degnan D. Methods for estimating confidence intervals in interrupted time series analyses of health interventions. J Clin Epidemiol 2009;62(2):143-8
   PubMed Web of Science ®Google Scholar
• Zeger SL. A regression model for time series of counts. Biometrika 1988;75(4):621-9
   Web of Science ®Google Scholar